Endovascular Therapy for Ischemic Stroke with Perfusion-Imaging Selection
Source: View publication →
In patients with acute ischemic stroke, proximal large vessel occlusion, and salvageable brain tissue on CT perfusion imaging, endovascular thrombectomy following intravenous alteplase dramatically improves reperfusion, early neurologic recovery, and functional independence compared to alteplase alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
EXTEND-IA cemented the role of advanced neuroimaging—specifically CT perfusion—in selecting patients for endovascular therapy. By demonstrating an unprecedented 71% rate of functional independence, the trial validated that combining rapid, targeted patient selection (small ischemic core and viable penumbra) with newer-generation stent retrievers yields dramatic clinical benefits. This firmly established mechanical thrombectomy as the standard of care for properly selected patients with acute anterior circulation large vessel occlusions.
Historical Context
Prior to 2014, major stroke trials (such as IMS III, MR RESCUE, and Synthesis Expansion) failed to prove the efficacy of endovascular therapy over standard medical management. These failures were largely attributed to older, less effective devices, slow times to reperfusion, and unrefined patient selection that included patients with massive unsalvageable infarcts. In late 2014, the MR CLEAN trial revolutionized stroke care by demonstrating a clear benefit for endovascular therapy. EXTEND-IA, published concurrently with the ESCAPE trial in early 2015, built upon MR CLEAN by integrating strict CT perfusion imaging criteria and newer-generation stent retrievers, yielding even larger treatment effects and definitively shifting global acute stroke guidelines.
Guided Discussion
High-yield insights from every perspective
What is the physiological concept of the ischemic penumbra, and how does CT perfusion imaging differentiate it from the ischemic core in acute stroke?
Key Response
The core represents irreversibly infarcted tissue marked by severely reduced cerebral blood flow and volume. The penumbra is hypoperfused but salvageable tissue, marked by increased mean transit time with relatively preserved blood volume due to autoregulation. Understanding this mismatch is foundational to grasping why reperfusion therapies like thrombectomy are time-critical and beneficial only when salvageable tissue remains.
A patient presents with an MCA stroke 3 hours after symptom onset. If CTA confirms an M1 occlusion, what are the immediate next steps according to EXTEND-IA protocols, and why is IV alteplase administered before thrombectomy rather than proceeding straight to the cath lab?
Key Response
Residents must know that IV alteplase should not be delayed to wait for endovascular therapy (EVT), nor should it be skipped if EVT is planned in eligible early-window patients. Alteplase treats distal emboli and begins dissolving the clot, while EVT mechanically removes the proximal large vessel occlusion that alteplase alone usually fails to clear.
EXTEND-IA required an ischemic core volume of less than 70 mL. How does this strict perfusion imaging criteria impact the number needed to treat (NNT) for functional independence, and what are the limitations of applying this strict cutoff in real-world clinical practice?
Key Response
By highly selecting patients with small cores and large penumbras, EXTEND-IA achieved a massive effect size and an exceptionally low NNT of around 3 for functional independence. However, fellows must recognize that strictly requiring advanced CTP may delay care or exclude patients with larger cores (e.g., ASPECTS 3-5) who might still derive some meaningful clinical benefit from EVT, a nuance later explored in trials like SELECT2 and RESCUE-Japan.
As an attending leading a stroke code, how do you balance the time delay of acquiring advanced CT perfusion imaging against the principle of time is brain when deciding on EVT for a patient presenting within 6 hours of onset?
Key Response
While EXTEND-IA highlights the utility of perfusion imaging, attendings must synthesize workflow efficiency. For patients within the early 0-6 hour window, standard non-contrast CT (evaluating ASPECTS) and CTA are often sufficient to proceed with EVT. Over-reliance on CTP in the early window can cause unnecessary delays, though it remains absolutely crucial for late-window (6-24 hr) selection.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The EXTEND-IA trial was terminated early due to overwhelming efficacy after only 71 patients were randomized. What are the statistical risks of truncating a randomized controlled trial early for benefit, particularly regarding the estimation of treatment effect size?
Key Response
Trials stopped early for benefit are known to systematically overestimate treatment effects due to random high bias. Researchers must critically evaluate whether the massive odds ratios seen in EXTEND-IA (such as the dramatically higher reperfusion rates) reflect the true population parameter or are inflated by early stopping rules, which impacts sample size and power calculations for subsequent trials.
From a peer-review perspective, how does the exclusive use of a single device (the Solitaire FR stent retriever) and specific automated perfusion software (RAPID) impact the external validity and generalizability of the trial?
Key Response
A rigorous reviewer would flag that standardizing the intervention and imaging to proprietary products minimizes confounding and maximizes internal validity, but inherently limits generalizability. It raises questions about whether the observed benefits are class-effects of all stent retrievers and aspiration catheters, and whether centers without access to automated RAPID software can achieve similar imaging selection accuracy.
Given the findings of EXTEND-IA alongside similar pivotal trials (like MR CLEAN and ESCAPE), how should AHA/ASA guidelines grade the recommendation for EVT in early-window (0-6 hours) acute ischemic stroke, and is perfusion imaging strictly mandated for this subgroup?
Key Response
EXTEND-IA contributed to a Class 1, Level of Evidence A recommendation for EVT in large vessel occlusion strokes within 6 hours. However, the committee determined that while EXTEND-IA used CTP to definitively prove the concept of salvageable tissue, advanced perfusion imaging is not mandatory for the 0-6 hour window (ASPECTS greater than or equal to 6 on non-contrast CT is sufficient) to avoid delaying reperfusion, whereas advanced imaging is required for the 6-24 hour extended window.
Clinical Landscape
Noteworthy Related Trials
MR CLEAN
Tested
Endovascular treatment plus usual care
Population
Patients with acute ischemic stroke and proximal arterial occlusion within 6 hours
Comparator
Usual care alone
Endpoint
Modified Rankin scale score at 90 days
DAWN Trial
Tested
Thrombectomy plus standard medical care
Population
Patients with acute ischemic stroke 6 to 24 hours after onset with clinical-core mismatch
Comparator
Standard medical care alone
Endpoint
Utility-weighted modified Rankin scale score at 90 days
DEFUSE 3
Tested
Endovascular thrombectomy plus standard medical therapy
Population
Patients with acute ischemic stroke 6 to 16 hours after onset with favorable perfusion imaging profile
Comparator
Standard medical therapy alone
Endpoint
Modified Rankin scale score at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis